Titre : Chimérisme

Chimérisme : Questions médicales fréquentes

Termes MeSH sélectionnés :

Neoplasm Recurrence, Local
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Chimérisme : Questions médicales les plus fréquentes", "headline": "Chimérisme : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Chimérisme : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-28", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Chimérisme" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Aberrations des chromosomes", "url": "https://questionsmedicales.fr/mesh/D002869", "about": { "@type": "MedicalCondition", "name": "Aberrations des chromosomes", "code": { "@type": "MedicalCode", "code": "D002869", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.365.590.175" } } }, "about": { "@type": "MedicalCondition", "name": "Chimérisme", "alternateName": "Chimerism", "code": { "@type": "MedicalCode", "code": "D046528", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Hui Li", "url": "https://questionsmedicales.fr/author/Hui%20Li", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States; Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States. Electronic address: hl9r@virginia.edu." } }, { "@type": "Person", "name": "Sandeep Singh", "url": "https://questionsmedicales.fr/author/Sandeep%20Singh", "affiliation": { "@type": "Organization", "name": "Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States." } }, { "@type": "Person", "name": "Hao Zhang", "url": "https://questionsmedicales.fr/author/Hao%20Zhang", "affiliation": { "@type": "Organization", "name": "Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China. haozhang@jnu.edu.cn." } }, { "@type": "Person", "name": "Xinrui Shi", "url": "https://questionsmedicales.fr/author/Xinrui%20Shi", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States." } }, { "@type": "Person", "name": "Yusheng Lin", "url": "https://questionsmedicales.fr/author/Yusheng%20Lin", "affiliation": { "@type": "Organization", "name": "Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Postoperative venous thromboembolism after surgery for locally recurrent rectal cancer.", "datePublished": "2024-08-20", "url": "https://questionsmedicales.fr/article/39164626", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12885-024-12799-1" } }, { "@type": "ScholarlyArticle", "name": "Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.", "datePublished": "2023-01-31", "url": "https://questionsmedicales.fr/article/36720507", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1759-7714.14805" } }, { "@type": "ScholarlyArticle", "name": "Development of a consensus-based delineation guideline for locally recurrent rectal cancer.", "datePublished": "2022-11-21", "url": "https://questionsmedicales.fr/article/36410547", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.radonc.2022.11.008" } }, { "@type": "ScholarlyArticle", "name": "The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.", "datePublished": "2022-08-08", "url": "https://questionsmedicales.fr/article/35939185", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10549-022-06680-7" } }, { "@type": "ScholarlyArticle", "name": "Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection.", "datePublished": "2022-05-29", "url": "https://questionsmedicales.fr/article/35643422", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12885-022-09650-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Variation génétique", "item": "https://questionsmedicales.fr/mesh/D014644" }, { "@type": "ListItem", "position": 4, "name": "Mutation", "item": "https://questionsmedicales.fr/mesh/D009154" }, { "@type": "ListItem", "position": 5, "name": "Aberrations des chromosomes", "item": "https://questionsmedicales.fr/mesh/D002869" }, { "@type": "ListItem", "position": 6, "name": "Chimérisme", "item": "https://questionsmedicales.fr/mesh/D046528" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Chimérisme - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Chimérisme", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-30", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Chimérisme", "description": "Comment diagnostiquer le chimérisme ?\nQuels tests sont utilisés pour le chimérisme ?\nLe chimérisme peut-il être détecté par échographie ?\nQuels signes cliniques peuvent indiquer un chimérisme ?\nLe chimérisme est-il héréditaire ?", "url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Chimérisme", "description": "Quels sont les symptômes du chimérisme ?\nLe chimérisme cause-t-il des douleurs ?\nPeut-on avoir des symptômes sans chimérisme ?\nLe chimérisme affecte-t-il la croissance ?\nY a-t-il des symptômes spécifiques au chimérisme ?", "url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Chimérisme", "description": "Peut-on prévenir le chimérisme ?\nY a-t-il des facteurs de risque pour le chimérisme ?\nLes tests prénataux peuvent-ils détecter le chimérisme ?\nLe chimérisme est-il lié à des pratiques médicales ?\nLes femmes enceintes doivent-elles se méfier du chimérisme ?", "url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Chimérisme", "description": "Comment traiter le chimérisme ?\nLe chimérisme nécessite-t-il une intervention chirurgicale ?\nLes médicaments peuvent-ils aider au chimérisme ?\nY a-t-il des traitements naturels pour le chimérisme ?\nLe suivi médical est-il nécessaire pour le chimérisme ?", "url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Chimérisme", "description": "Quelles complications peuvent survenir avec le chimérisme ?\nLe chimérisme peut-il causer des cancers ?\nComment gérer les complications du chimérisme ?\nLe chimérisme affecte-t-il le système immunitaire ?\nY a-t-il des risques de rejet avec le chimérisme ?", "url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Chimérisme", "description": "Quels sont les facteurs de risque du chimérisme ?\nLe chimérisme est-il plus fréquent chez certaines populations ?\nLes greffes augmentent-elles le risque de chimérisme ?\nLes antécédents médicaux influencent-ils le chimérisme ?\nLe chimérisme est-il lié à des facteurs environnementaux ?", "url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer le chimérisme ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par analyse génétique, notamment par PCR ou séquençage." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le chimérisme ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'analyse de l'ADN, les tests de compatibilité tissulaire et les marqueurs génétiques." } }, { "@type": "Question", "name": "Le chimérisme peut-il être détecté par échographie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'échographie ne peut pas détecter le chimérisme, seul un test génétique est fiable." } }, { "@type": "Question", "name": "Quels signes cliniques peuvent indiquer un chimérisme ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des signes cliniques peuvent inclure des anomalies immunitaires ou des différences phénotypiques." } }, { "@type": "Question", "name": "Le chimérisme est-il héréditaire ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, le chimérisme n'est généralement pas héréditaire, il résulte d'événements embryonnaires." } }, { "@type": "Question", "name": "Quels sont les symptômes du chimérisme ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, mais peuvent inclure des anomalies cutanées ou des troubles immunitaires." } }, { "@type": "Question", "name": "Le chimérisme cause-t-il des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le chimérisme en soi ne cause pas de douleurs, mais des complications peuvent en entraîner." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans chimérisme ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux symptômes peuvent être causés par d'autres conditions médicales." } }, { "@type": "Question", "name": "Le chimérisme affecte-t-il la croissance ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Il peut affecter la croissance si des anomalies génétiques ou hormonales sont présentes." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques au chimérisme ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des différences de pigmentation ou des anomalies immunitaires peuvent être spécifiques." } }, { "@type": "Question", "name": "Peut-on prévenir le chimérisme ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Le chimérisme ne peut pas être prévenu car il résulte d'événements embryonnaires." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de risque pour le chimérisme ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque incluent des grossesses multiples ou des transfusions sanguines." } }, { "@type": "Question", "name": "Les tests prénataux peuvent-ils détecter le chimérisme ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les tests prénataux standard ne détectent pas le chimérisme, des tests génétiques spécifiques sont nécessaires." } }, { "@type": "Question", "name": "Le chimérisme est-il lié à des pratiques médicales ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines pratiques comme les greffes peuvent augmenter le risque de chimérisme." } }, { "@type": "Question", "name": "Les femmes enceintes doivent-elles se méfier du chimérisme ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de mesures préventives spécifiques pour les femmes enceintes concernant le chimérisme." } }, { "@type": "Question", "name": "Comment traiter le chimérisme ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement dépend des symptômes et peut inclure des thérapies immunosuppressives." } }, { "@type": "Question", "name": "Le chimérisme nécessite-t-il une intervention chirurgicale ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Rarement, sauf si des complications graves nécessitent une intervention spécifique." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider au chimérisme ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments immunosuppresseurs peuvent être prescrits pour gérer les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour le chimérisme ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitements naturels prouvés pour le chimérisme, consultez un médecin." } }, { "@type": "Question", "name": "Le suivi médical est-il nécessaire pour le chimérisme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour surveiller les complications potentielles." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le chimérisme ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles immunitaires, des rejets de greffe ou des cancers." } }, { "@type": "Question", "name": "Le chimérisme peut-il causer des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines formes de chimérisme peuvent augmenter le risque de cancers spécifiques." } }, { "@type": "Question", "name": "Comment gérer les complications du chimérisme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi médical régulier et des traitements adaptés aux symptômes." } }, { "@type": "Question", "name": "Le chimérisme affecte-t-il le système immunitaire ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le chimérisme peut entraîner des dysfonctionnements du système immunitaire." } }, { "@type": "Question", "name": "Y a-t-il des risques de rejet avec le chimérisme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le rejet peut survenir si des cellules étrangères sont reconnues par le système immunitaire." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque du chimérisme ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les grossesses multiples et les transfusions sanguines sont des facteurs de risque connus." } }, { "@type": "Question", "name": "Le chimérisme est-il plus fréquent chez certaines populations ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de données précises, mais les grossesses multiples peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les greffes augmentent-elles le risque de chimérisme ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les greffes d'organes peuvent introduire des cellules étrangères, entraînant un chimérisme." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le chimérisme ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de transfusions ou de greffes peuvent augmenter le risque de chimérisme." } }, { "@type": "Question", "name": "Le chimérisme est-il lié à des facteurs environnementaux ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de preuves solides liant le chimérisme à des facteurs environnementaux." } } ] } ] }

Sources (10000 au total)

Postoperative venous thromboembolism after surgery for locally recurrent rectal cancer.

Local recurrence is common after curative resections of rectal cancer. Surgical resection is considered a primary curative treatment option for patients with locally recurrent rectal cancer (LRRC). LR... From April 2010 to March 2022, a total of 166 patients underwent surgery for LRRC in the pelvic region at our institutions. Clinicopathological background and VTE incidence were compared retrospective... Among the 166 patients included in the study, 55 patients (33.1%) needed sacral resection. Pharmacological prophylaxis for prevention of VTE was performed in 121 patients (73.3%), and the incidence of... This study demonstrates that surgery for LRRC combined with sacral resection could be a significant risk factor for VTE....

Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.

The effectiveness of local therapy has been reported in patients with oligo-recurrence of non-small cell lung cancer (NSCLC), a metachronous recurrence with a limited number of recurrences, which can ... From 2004 to 2014, 811 patients underwent complete resection for NSCLC at Kitasato University Hospital and, of these, 244 patients developed recurrence. Oligo-recurrence was defined as the presence of... We retrospectively examined and compared the effects of EGFR-TKIs with those of radical local therapy in patients with oligo-recurrent EGFR-mutated NSCLC. The five-year post-recurrence survival (PRS) ... Radical local therapy did not affect PRS in patients with oligo-recurrent EGFR-mutated NSCLC. Even in cases of oligo-recurrence, the administration of local therapy in patients with EGFR-mutated NSCLC...

Development of a consensus-based delineation guideline for locally recurrent rectal cancer.

Neoadjuvant chemoradiotherapy (nCRT) is used in locally recurrent rectal cancer (LRRC) to increase chances of a radical surgical resection. Delineation in LRRC is hampered by complex disease presentat... Eight radiation oncologists, from Dutch and Swedish expert centres, participated in two meetings, delineating GTV and CTV in six cases. Regions at-risk for re-recurrence or irradical resection were id... Inter-observer variation in delineation of LRRC appeared large. Multidisciplinary evaluation per case is beneficial in determining target volumes. The following consensus regarding target volumes was ... This study provides a first consensus-based delineation guideline for LRRC. Analyses of re-recurrences is needed to understand disease behaviour and to optimize delineation guidelines accordingly....

The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary.

Describes the relevance of -various classification methods for ipsilateral breast tumour recurrence (IBTR) as either true recurrence (TR) or new primary (NP) on both disease-specific survival (DSS) an... Two hundred and thirty-four of 4359 women undergoing breast-conserving therapy experienced IBTR. We compared the impact of four known classification methods and two newly created classification method... For three of the methods, a better DSS was observed for NP compared to TR with the hazard ratio (HR) ranging from 0.5 to 0.6. The new Twente method classification, comprising all classification criter... IBTR classified as TR or NP has a prognostic value for both DSS and DMFS, but depends on the classification method used. Developing and validating a generally accepted form of classification are imper...

Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection.

The international consensus guidelines for intraductal papillary mucinous neoplasm of the pancreas (IPMN) presented clinical features as indications for surgery. Whereas surveillance for recurrence, i... This study aimed to assess the clinical features of recurrence at the remnant pancreas (Rem-Panc) and extra-pancreas (Ex-Panc) after surgery for IPMN. Ninety-one patients of IPMN that underwent detail... The IPMNs were finally diagnosed as low-grade dysplasia (LDA, n = 42), high-grade dysplasia (HAD, n = 19), and invasive carcinoma (IPMC, n = 30). Recurrence was observed in 26 patients (29%), of which... The risk factors for Rem-Panc and Ex-Panc recurrence differ. Therefore, optimal surveillance on these features is desirable to ensure that repeat pancreatectomy for Rem-Panc recurrence can be an appro...

Brain magnetic resonance spectroscopy to differentiate recurrent neoplasm from radiation necrosis: A systematic review and meta-analysis.

Postradiation treatment necrosis is one of the most serious late sequelae and appears within 6 months. The magnetic resonance spectroscopy imaging (MRSI) has been used for the detection of brain tumor... The research was performed in accordance with the preferred reporting items for systematic review and meta-analysis guidelines. International electronic databases including 15 English sources were inv... Nine studies were enrolled in the meta-analysis with a total of 354 patients (203 male and 151 female) whose average age ranged from 4 to 74 years. Anbarloui et al., Elias et al., Nemattalla et al., S... MR spectroscopy is effective in distinguishing recurrent brain tumors from necrosis. Our meta-analysis revealed that Cho/NAA, Cho/Cr, and NAA/Cr ratios were significantly better predictor of detected ...

A systematic review of the pathological determinants of outcome following resection by pelvic exenteration of locally advanced and locally recurrent rectal cancer.

Despite multimodal therapy 5-15% of patients who undergo resection for advanced rectal cancer (LARC) will develop local recurrence. Management of locally recurrent rectal cancer (LRRC) presents a sign... A systematic review was carried out searching MEDLINE, EMBASE and COCHRANE Trials database for all studies assessing pathological factors influencing survival following pelvic exenteration for LARC or... Nine cohort studies met inclusion criteria, reporting outcomes for 2864 patients. Meta-analysis was not possible due to significant heterogeneity of reported outcomes. Resection margin status and noda... Pathological resection margin status is widely demonstrated to influence disease free and overall survival following pelvic exenteration for rectal cancer. With increasing R0 rates, other adverse tumo...

Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness.

A first pilot study showed that an image-guided navigation system could improve resection margin rates in locally advanced (LARC) and locally recurrent rectal cancer (LRRC) patients. Incremental surgi... A Markov decision model was constructed to estimate the expected costs and outcomes for navigated and standard surgery. The input parameters were based on pilot data from a prospective (navigation coh... Based on this early evaluation, navigated surgery showed incremental costs of €3141 and €2896 in LARC and LRRC. In LARC, navigated surgery resulted in 2.05 Quality-Adjusted Life Years (QALYs) vs 2.02 ... Adding navigation system use is expected to be cost-effective in LRRC and has the potential to become cost-effective in LARC. To increase the probability of being cost-effective, it is crucial to opti...

The role of surgery in recurrent local cerebral metastases: a multi-institutional retrospective analysis.

Local recurrent brain metastases are defined as lesions that recur in the brain at the same site after a previous local therapy. In patients already submitted to surgery, a second operation may be pot... 37 patients submitted to surgery for a local, histologically confirmed, recurrent brain metastases between 2000 and 2022 were retrospectively analyzed with respect to the following parameters: age, hi... A significant improvement of post-operative KPS status was obtained after second surgery. At multivariate analysis better results in terms of OS were achieved in patients with a pre-operative KPS ≥ 70... Surgical resection of local recurrent brain metastases may improve patients ́ neurologic conditions allowing more time for systemic therapies to act with a low incidence of surgery-related morbidity a...

Salvage radiotherapy for locally recurrent cervical and endometrial carcinoma: clinical outcomes and toxicities.

The management of locally recurrent gynecological carcinoma remains a challenge due to the limited availability of data. This study aims to share our institutional experience in using definitive radio... The study retrospectively reviewed 20 patients in our hospital completing salvage 3D image-based HDR brachytherapy, with or without EBRT, for locally recurrent cervical and endometrial carcinoma after... During a median observation period of 21 months, the study reported a tumor objective response rate of 95%. The 3-year DFS and OS rates were 89.4% and 90.9%, respectively. The EBRT combined with brach... 3D image-guided brachytherapy combined with EBRT shows effective tumor control and acceptable toxicity profile for women with locally recurrent gynecologic cancer. The success in managing vaginal recu...